skip to Main Content

Publications 2010

The metabolism and disposition of a potent inhibitor of hepatitis C virus NS3/4A protease.

Monteagudo E, Fonsi M, Chu X, Bleasby K, Evers R, Pucci V, Orsale MV, Cianetti S, Ferrara M, Harper S, Laufer R, Rowley M, Summa V. (2010)
Xenobiotica. 2010 Dec;40(12):826-39.

More info on PubMed.gov

Development of 2-pyrrolidinyl-N-methyl pyrimidones as potent and orally bioavailable HIV integrase inhibitors.

Ferrara M, Fiore F, Summa V, Gardelli C. (2010)
Bioorg Med Chem Lett. 2010 Sep 1;20(17):5031-4.

More info on PubMed.gov

A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma.

Peruzzi D, Gavazza A, Mesiti G, Lubas G, Scarselli E, Conforti A, Bendtsen C, Ciliberto G, La Monica N, Aurisicchio L. (2010)
Mol Ther. 2010 Aug;18(8):1559-67.

More info on PubMed.gov

Immunological markers of cancer vaccine efficacy and their clinical relevance.

Cipriani B. (2009)
Biomark Med. 2009 Jun;3(3):253-64.

More info on PubMed.gov

Allosteric inhibitors of hepatitis C virus NS5B polymerase thumb domain site II: structure-based design and synthesis of new templates.

Malancona S, Donghi M, Ferrara M, Martin Hernando JI, Pompei M, Pesci S, Ontoria JM, Koch U, Rowley M, Summa V. (2010)
Bioorg Med Chem. 2010 Apr 15;18(8):2836-48.

More info on PubMed.gov

Enhancement of intestinal absorption of 2-methyl cytidine prodrugs.

Cianetti S, Cooper VB, Attenni B, Pucci V, Fiore F, Giuliano C, Laufer R, Gardelli C, Monteagudo E, Narjes F, Pearce GE, Rowley M. (2010)
Drug Deliv. 2010 May;17(4):214-22.

More info on PubMed.gov

Identification and SAR of novel pyrrolo[1,2-a]pyrazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1).

Pescatore G, Branca D, Fiore F, Kinzel O, Bufi LL, Muraglia E, Orvieto F, Rowley M, Toniatti C, Torrisi C, Jones P. (2010)
Bioorg Med Chem Lett. 2010 Feb 1;20(3):1094-9.

More info on PubMed.gov

Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells.

Ferrigno F, Branca D, Kinzel O, Lillini S, Llauger Bufi L, Monteagudo E, Muraglia E, Rowley M, Schultz-Fademrecht C, Toniatti C, Torrisi C, Jones P. (2010)
Bioorg Med Chem Lett. 2010 Feb 1;20(3):1100-5.

More info on PubMed.gov

Discovery and SAR of novel, potent and selective hexahydrobenzonaphthyridinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).

Torrisi C, Bisbocci M, Ingenito R, Ontoria JM, Rowley M, Schultz-Fademrecht C, Toniatti C, Jones P. (2010)
Bioorg Med Chem Lett. 2010 Jan 15;20(2):448-52.

More info on PubMed.gov

Synthesis and biological evaluation of substituted 2-phenyl-2H-indazole-7-carboxamides as potent poly(ADP-ribose) polymerase (PARP) inhibitors.

Scarpelli R, Boueres JK, Cerretani M, Ferrigno F, Ontoria JM, Rowley M, Schultz-Fademrecht C, Toniatti C, Jones P. (2010) Bioorg Med Chem Lett. 2010 Jan 15;20(2):488-92.

More info on PubMed.gov

Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs.

Peruzzi D, Mesiti G, Ciliberto G, La Monica N, Aurisicchio L. (2010)
Vaccine. 2010 Feb 3;28(5):1201-8.

More info on PubMed.gov

Novel P2-P4 macrocyclic inhibitors of HCV NS3/4A protease by P3 succinamide fragment depeptidization strategy.

Pompei M, Di Francesco ME, Pesci S, Koch U, Vignetti SE, Veneziano M, Pace P, Summa V. (2010)
Bioorg Med Chem Lett. 2010 Jan 1;20(1):168-74.

More info on PubMed.gov

Novel potent apoA-I peptide mimetics that stimulate cholesterol efflux and pre-beta particle formation in vitro.

Ingenito R, Burton C, Langella A, Chen X, Zytko K, Pessi A, Wang J, Bianchi E. (2010)
Bioorg Med Chem Lett. 2010 Jan 1;20(1):236-9.

More info on PubMed.gov

Turbulent flow chromatography TFC-tandem mass spectrometry supporting in vitro/vivo studies of NCEs in high throughput fashion.

Verdirame M, Veneziano M, Alfieri A, Di Marco A, Monteagudo E, Bonelli F. (2010)
J Pharm Biomed Anal. 2010 Mar 11;51(4):834-41.

More info on PubMed.gov
Back To Top